Eric C. Burton, M.D.
- Center for Cancer Research
- National Cancer Institute
- Bloch Building 82, Room 243
- Bethesda, MD 20892
Dr. Burton is a neuro-oncologist who provides care for adults with primary brain tumors. His particular research interest is determining the optimal treatment for older patients with primary brain tumors. As a member of the Neuro-Oncology Branch (NOB), he applies his extensive neuro-oncology experience to developing research projects that utilize population-based data analysis to answer difficult clinical questions. He also develops clinical trials in various sub-populations, such as geriatric patients. The overarching goal of Dr. Burton’s research is to provide the best possible care to all brain tumor patients, while also determining the best regimen for each individual—keeping in mind their cognitive, functional, and physiological limitations due to the disease.
Areas of Expertise
1) Neuro-oncology 2) Brain tumors 3) Clinical trials 4) Geriatric oncology 5) Glioblastoma
Information for Patients
Learn more about our clinical trials and the highly specialized care teams that lead them.
After working with brain tumor patients from underprivileged and under-served areas, Dr. Burton has expanded his clinical interests to determining the various factors that contribute to varying patient responses to therapy with a specific focus on older populations. Utilizing the resources and extensive collaborative opportunities at NIH and within the Neuro-Oncology Branch (NOB), Dr. Burton is building a research program to determine the best clinical care regimen for brain tumor patients by utilizing the biological and physiological differences between patients.
Failure to complete standard radiation therapy in glioblastoma patients: patterns from a national database with implications for survival and therapeutic decision making in older glioblastoma patients.
The Impact of Timing of Adjuvant Therapy on Survival for Patients with Glioblastoma: An analysis of the National Cancer Database.
Survival in elderly patients with glioblastoma in the USA: A comparison of bevacizumab-based and non-bevacizumab-based regimens
Survival Impact of Prolonged Radiation Therapy for Patients with Glioblastoma Treated with Combined-Modality Therapy
Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old with Newly Diagnosed Glioblastoma
Eric C. Burton, M.D.
Dr. Burton received both his Bachelor of Science and Doctor of Medicine degrees from the University of Michigan in Ann Arbor. Following medical school, he decided to pursue a residency in neurology at the University of Chicago. Later, looking to combine his neurology training with cancer care, he pursued a neuro-oncology fellowship at the University of California San Francisco (UCSF). He served as a faculty member at both UCSF and the University of California Los Angeles (UCLA) before joining the University of Louisville’s Brown Cancer Center and eventually becoming the director of neuro-oncology. He began his tenure at the Neuro-Oncology Branch (NOB) in early 2019, and continues to serve patients in a clinical capacity in addition to developing clinical trials for select brain tumor patient populations.
Honors, Awards and Leadership
- Top Doctor, University of Louisville - 2017, 2018
- Robert Magnin Newman Fellowship Award (UCSF)
- M.D. with Distinction, University of Michigan – Ann Arbor
Select Societies and Initiatives
- Society for Neuro-oncology
- American Society for Clinical Oncology
- American Academy of Neurology